8 results on '"Costa, Renato Patrizio"'
Search Results
2. Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients
- Author
-
Caffo, Orazio, primary, Frantellizzi, Viviana, additional, Monari, Fabio, additional, Sbrana, Andrea, additional, Costa, Renato Patrizio, additional, Pinto, Carmine, additional, Tucci, Marcello, additional, Baldari, Sergio, additional, Facchini, Gaetano, additional, Bortolus, Roberto, additional, Alongi, Filippo, additional, Alongi, Pierpaolo, additional, Palermo, Antonio, additional, Fanti, Stefano, additional, Biasco, Elisa, additional, Murabito, Alessandra, additional, Filice, Angelina, additional, Zichi, Clizia, additional, Pignata, Salvatore, additional, Borsatti, Eugenio, additional, Salgarello, Matteo, additional, Spada, Massimiliano, additional, Cortesi, Enrico, additional, and Vincentis, Giuseppe De, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Autologous peripheral blood mononuclear cells for the treatment of lower extremity lymphedema: A preliminary report.
- Author
-
Bellisi, Mario, Guttuso, Ilenia, Murabito, Alessandra, Corigliano, Alessandro, Filice, Rossella, Trovato, Christian, and Costa, Renato Patrizio
- Subjects
MONONUCLEAR leukocytes ,LYMPHEDEMA - Abstract
Lymphedema is a chronic devastating disease characterized by the accumulation of fluid in the extremities, tissue progressive changes such as adipose tissue deposition and fibrosis. To restore the functionality and structural integrity of the damaged lymphatic vessels, autologous peripheral blood mononuclear cells (PBMNC) was implanted in 3 sessions, 4 weeks apart, in the affected limb. Each patient was followed for 6 months, monitoring changes in the limb volume. Lymphangiogenesis was evaluated by lymphoscintigraphy, and the monitoring of quality of life. A rapid reduction in the volume of the limbs was observed: Twenty-four point 5 percent of volume reduction after the first implant, 18.5% after the second, and 15.3% at 6 months after the third (p<0.05 vs baseline). Lymphoscintigraphy showed a hyper fixation of the tracer along the ipsilateral iliac axis not appreciable at baseline. Implants of autologous PBMNC in patients with primary lower limb lymphedema seems to be a feasible, effective therapy option. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?
- Author
-
Costa, Renato Patrizio, additional, Tripoli, Vincenzo, additional, Princiotta, Alessandro, additional, Murabito, Alessandra, additional, Licari, Maria, additional, Mauceri, Rodolfo, additional, Campisi, Giuseppina, additional, and Pinto, Antonio, additional
- Published
- 2019
- Full Text
- View/download PDF
5. Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
- Author
-
Matteo Bauckneht, Sara Elena Rebuzzi, Marta Ponzano, Roberto Borea, Alessio Signori, Viviana Frantellizzi, Elisa Lodi Rizzini, Manlio Mascia, Valentina Lavelli, Alberto Miceli, Maria Silvia De Feo, Antonio Rosario Pisani, Susanna Nuvoli, Vincenzo Tripoli, Alessio Giuseppe Morganti, Paolo Mammucci, Salvatore Caponnetto, Guglielmo Mantica, Angelo Domenico Di Nicola, Carlo Villano, Luca Cindolo, Silvia Morbelli, Gianmario Sambuceti, Stefano Fanti, Renato Patrizio Costa, Angela Spanu, Giuseppe Rubini, Fabio Monari, Giuseppe De Vincentis, Giuseppe Fornarini, Bauckneht, Matteo, Rebuzzi, Sara Elena, Ponzano, Marta, Borea, Roberto, Signori, Alessio, Frantellizzi, Viviana, Lodi Rizzini, Elisa, Mascia, Manlio, Lavelli, Valentina, Miceli, Alberto, De Feo, Maria Silvia, Pisani, Antonio Rosario, Nuvoli, Susanna, Tripoli, Vincenzo, Morganti, Alessio Giuseppe, Mammucci, Paolo, Caponnetto, Salvatore, Mantica, Guglielmo, Di Nicola, Angelo Domenico, Villano, Carlo, Cindolo, Luca, Morbelli, Silvia, Sambuceti, Gianmario, Fanti, Stefano, Costa, Renato Patrizio, Spanu, Angela, Rubini, Giuseppe, Monari, Fabio, De Vincentis, Giuseppe, and Fornarini, Giuseppe
- Subjects
clinical factors ,European Medicines Agency restricted use ,inflammatory indices ,metastatic castration-resistant prostate cancer ,neutrophil-to-lymphocyte ratio ,Radium-223 ,treatment completion ,inflammatory indice ,Cancer Research ,Oncology ,clinical factor - Abstract
Simple Summary Radium-223 prolongs overall survival in metastatic castration-resistant prostate cancer patients with bone metastases. However, prognosis after Radium-223 administration varies among patients. One possible reason for this heterogeneity could rely on the suboptimal selection of patients with unfavourable prognostic factors. Moreover, in 2018, the European Medicines Agency limited the Radium-223 prescription to patients pre-treated with at least two systemic therapies or ineligible for any systemic treatment and more than six bone lesions. This moved Radium-223 treatment to the later stages of the disease, making the patient selection process even more challenging. In the BIO-Ra study, we previously combined peripheral inflammatory indices and clinical factors in a composite score able to stratify the prognosis of these patients since baseline. In the present study, the BIO-Ra score was also a reliable prognostic tool in the current clinical scenario, with a potential added value in the patient's selection for Radium-223 treatment. The multicentric retrospective BIO-Ra study combined inflammatory indices from peripheral blood and clinical factors in a composite prognostic score for metastatic castration-resistant prostate cancer patients receiving Radium-223 (Ra-223). In the present study, we evaluated (i) the prognostic power of the BIO-Ra score in the framework of the restricted use of Ra-223 promoted by the European Medicines Agency in 2018; (ii) the treatment completion prediction of the BIO-Ra score. Four hundred ninety-four patients from the BIO-Ra cohort were divided into three risk classes according to the BIO-Ra score to predict the treatment completion rate (p < 0.001 among all the three groups). Patients receiving Ra-223 after restriction (89/494) were at later stages of the disease compared with the pre-restriction cohort (405/494), as a higher percentage of BIO-Ra high-risk classes (46.1% vs. 34.6%) and lower median Overall survival (12.4 vs. 23.7 months, p < 0.001) was observed. Despite this clinically relevant difference, BIO-Ra classes still predicted divergent treatment completion rates in the post-restriction subgroup (72%, 52.2%, and 46.3% of patients belonging to low-, intermediate-, and high-risk classes, respectively). Although the restricted use has increased patients at higher risk with unfavourable outcome after Ra-223 treatment, the BIO-Ra score maintains its prognostic value.
- Published
- 2022
- Full Text
- View/download PDF
6. Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?
- Author
-
Rodolfo Mauceri, Giuseppina Campisi, Maria Licari, A. Princiotta, Antonio Pinto, Renato Costa, Vincenzo Tripoli, Alessandra Murabito, Costa, Renato Patrizio, Tripoli, Vincenzo, Princiotta, Alessandro, Murabito, Alessandra, Licari, Maria, Mauceri, Rodolfo, Campisi, Giuseppina, and Pinto, Antonio
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Radium-223 ,medicine.medical_specialty ,Bone disease ,lcsh:R895-920 ,Case Report ,030218 nuclear medicine & medical imaging ,radium 223 ,03 medical and health sciences ,Prostate cancer ,breast cancer ,0302 clinical medicine ,Breast cancer ,medicine ,Craniofacial ,Prospective cohort study ,business.industry ,Bone metastases ,Cancer ,medicine.disease ,Surgery ,Bone metastase ,osteonecrosis of the jaw ,030220 oncology & carcinogenesis ,business ,Osteonecrosis of the jaw ,medicine.drug - Abstract
Osteonecrosis of the jaw (ONJ) is a rare and severe necrotic bone disease reflecting a compromise in the body's osseous healing mechanisms and unique to the craniofacial region. Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In 2018, a Caucasian 54-year-old woman presented to our institution for a breast cancer with bone metastases. Since the patient refused any treatment and taking into account the bone disease, our multidisciplinary team evaluated a supplementary strategy with radium 223. A total of six treatments were planned with a dose of 50 KBq/kg every 4 weeks according to Phase 2 data. Four days after the second cycle administration, the patient presented for examination with a self-extracted necrotic bone fragment. Oroantral communication remained in the absence of algic symptomatology or suppuration. The multidisciplinary approach between oncologists, nuclear physicians, and dental health teams is crucial throughout the treatment process to avoid unnecessary suffering in patients at risk. More prospective studies are needed; however, considering the limitation of the present case, radio 223 may play an adjuvant role in the medical treatment of cancer patients with active ONJ.
- Published
- 2019
7. Ra223 in Bone Metastases with Osteolytic Activity.
- Author
-
Costa RP, Cardile D, Murabito A, Tripoli V, and Verderame F
- Abstract
Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development for this radiopharmaceutical., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
8. The intraoperative use of the mini-gamma camera (MGC) in the surgical treatment of primary hyperparathyroidism: Technical reports and immediate results from the initial experience.
- Author
-
Scerrino G, Castorina S, Melfa GI, Lo Piccolo C, Raspanti C, Richiusa P, Costa RP, and Gulotta G
- Subjects
- Female, Humans, Minimally Invasive Surgical Procedures, Radionuclide Imaging, Gamma Cameras, Hyperparathyroidism, Primary surgery, Monitoring, Intraoperative instrumentation, Parathyroidectomy
- Abstract
Introduction: The treatment of primary hyperparathyroidism consists almost exclusively in the parathyroidectomy. The preoperative imaging (ultrasonography, 99mTc sestamibi scan) can allow to localize the pathologic gland and perform minimally-invasive focused techniques, but in presence of ectopic or intrathyroidal glands, parathyroid hyperplasia or coexistent thyroid disease, the sensitivity of these imaging techniques worsens. The present study shows a new technique of preoperative scintigraphic imaging and describes the early applications of this technique investigating if it is useful in improving the localization of the pathologic parathyroid., Methods: Five female patients were enrolled in the study. In all cases, we performed a parathyroidectomy using a systematic recognition of the four parathyroid glands under intraoperative PTH monitoring, adding the use of the intraoperative gamma camera to usual surgical procedures. We evaluate the concordance of the results of the intraoperative gamma camera with the preoperative diagnosis, the intraoperative PTH monitoring and the intraoperative findings. Moreover, the results of the treatment one month after the surgical procedure were also considered., Results: The results of intraoperative scintigraphy were always concordant with intraoperative findings. The intraoperative PTH monitoring and the results of the follow-up confirmed the completeness of the excision, at least in a short period of observation., Conclusions: The intraoperative gamma camera could help to improve the localization of a pathologic parathyroid gland. These results could be useful in improving the results of minimally invasive surgery as well as "difficult" situations.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.